|
Psychiatric drugs
|
|
(-)-OSU6162 [16]
|
62 (2, placebo)
|
30 mg, 60 mg/day, 2
|
MFS, CGI
|
Not significant
|
|
Duloxetine [17]
|
60 (2, placebo)
|
60–120 mg/day, 12
|
MFI (general fatigue)
|
Not significant
|
|
Clonidine-hydrochloride [18]
|
188 (3, placebo, HC)
|
50 μg or 100 μg/day, 9
|
Number of steps per day
|
Not significant
|
|
Methylphenidate [19]
|
60 (crossover, placebo)
|
10 mg/day, 4
|
CIS (fatigue, concentration) VAS (fatigue, concentration)
|
CIS (fatigue): P < 0.01, VAS: P < 0.01
|
|
Galantamine hydrobromide [20]
|
434 (5, placebo)
|
7.5–30 mg/day, 16
|
CGI
|
Not significant
|
|
Moclobemide [21]
|
90 (2, placebo)
|
450–600 mg/day, 6
|
Globally improved cases, KPS, POMS
|
Not significant
|
|
Fluoxetine [22]
|
96 (2, placebo)
|
20 mg/day, 8
|
CIS (fatigue)a
|
Not significant
|
|
Galantamine hydrobromide [23]
|
49 (2, placebo)
|
30 mg/day, 8
|
VAS (fatigue)
|
Not significant
|
|
Immunomodulators
|
|
BioBran MGN-3 [24]
|
71 (2, placebo)
|
6 g/day, 8
|
Chalder scale(physical)
|
Not significant
|
|
Staphypan Berna [25]
|
100 (2, placebo)
|
0.1–1.0 ml/week and 1.0 ml/4 weeks, 24
|
CGI, CPRS
|
CGI: P < 0.001, CPRS: P < 0.01
|
|
Gamma globulin [26]
|
71 (2, placebo)
|
1 gm/kg 3 times/month, 8
|
Mean functional score
|
P < 0.05 (6 month)
|
|
Poly(I):poly(C12U) [27]
|
92 (2, placebo)
|
400–800 mg/week, 24
|
KPSa
|
P < 0.05
|
|
Cortisol
|
|
Hydrocortisone + 9-alfa-fludrocortisone [28]
|
80 (crossover, placebo)
|
5 mg + 50 μg/day, 12
|
VAS (fatigue)
|
Not significant
|
|
Fludrocortisone acetate [29]
|
100 (2, placebo)
|
0.1 mg/day, 9
|
Global wellness score
|
Not significant
|
|
Hydrocortisone [30]
|
32 (crossover, placebo)
|
5 or 10 mg/day, 4
|
Chalder scale, CGI
|
Chalder scale: P < 0.01
|
|
Hydrocortisone [31]
|
70 (2, placebo)
|
16 mg/m2/day, 12
|
Global wellness score
|
Not significant
|
|
Fludrocortisone acetate [32]
|
25 (crossover, placebo)
|
0.1–0.2 mg/day, 6
|
VAS, SF-36a
|
Not significant
|
|
Mitochondrial modulators
|
|
KPAX002 [33]
|
128 (2, placebo)
|
12 mg/day, 12
|
CIS (total score)
|
Not significant
|
|
CoQ10 + NADH [34]
|
73 (2, placebo)
|
200 mg + 20 mg/day, 8
|
FIS-40 (total score)
|
P < 0.05
|
|
NADH [35]
|
26 (crossover, placebo)
|
10 mg/day, 4
|
Self-developed subject symptom scoring system
|
Not significant
|
|
Nutrients
|
|
Acclydine [36]
|
57 (2, placebo)
|
1000–125 mg/day, 14
|
CIS (fatigue), SIP-8
|
Not significant
|
|
Polynutrient supplement [37]
|
63 (2, placebo)
|
125 ml/day, 10
|
CIS (fatigue), N of CDC symptoms, SIP-8
|
Not significant
|
|
Others
|
|
Anakinra [38]
|
50 (2, placebo)
|
100 mg/day, 4
|
CIS (fatigue)
|
Not significant
|
|
Ondansetron [39]
|
67 (2, placebo)
|
16 mg/day, 10
|
CIS (fatigue), SIP-8
|
Not significant
|
|
Homeopathic treatment [40]
|
103 (2, placebo)
|
Not fixed, 24
|
MFI
|
Not significant
|
